Core Insights - Nxera Pharma has entered into a license agreement with a newly established independent company, NewCo, to advance its G protein-coupled receptor (GPCR)-targeted program [1][2] - Nxera has received an equity stake in NewCo and is entitled to milestone payments and royalties upon successful development and commercialization of the asset [2] - Nxera retains rights to develop and commercialize the asset in Japan and certain Asia-Pacific territories in the future [2] - The partnership with NewCo is aimed at maximizing the value of the Program and enabling it to reach patients [3] - Nxera may participate in a Series A financing round of NewCo alongside major global investment firms [3] - The impact of the agreement on Nxera's consolidated financial results for the fiscal year ending 31 December 2026 is under review [4] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines for patients with unmet needs in Japan and globally [6] - The company has established a new-generation commercial business in Japan and is advancing an extensive pipeline through its unique NxWave™ GPCR structure-based drug discovery platform [6] - Nxera operates in key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under ticker 4565 [6]

Core Insights - Ipsen reported strong financial results for FY 2025, with total sales reaching €3,675.9 million, an increase of 8.1% as reported and 10.9% at constant exchange rates (CER) compared to FY 2024 [2][4] - The company achieved a core operating income of €1,294.1 million, reflecting a growth of 16.7% and a core operating margin of 35.2%, up by 2.6 percentage points [2][4] - Core consolidated net profit increased by 17.6% to €1,009.1 million, with core earnings per share rising to €12.09, a 17.8% increase [2][4] - Ipsen anticipates continued double-digit sales growth for 2026, projecting total sales growth greater than 13.0% at CER, driven by portfolio acceleration and improved outlook for Somatuline [3][5][6] Financial Performance - Total sales for FY 2025 were €3,675.9 million, with growth driven by Oncology (4.1%), Rare Disease (102.5%), and Neuroscience (9.7%) [4] - Somatuline® sales grew by 4.3%, while other products excluding Somatuline achieved double-digit sales growth of 14.2% [4] - Free cash flow for FY 2025 was €1,000.6 million, a 29.2% increase from the previous year [2] Pipeline and Innovation - Ipsen made significant advancements in its pipeline, including multiple regulatory and clinical milestones, and the acquisition of ImCheck Therapeutics [4][15] - Five major regulatory and clinical milestones are expected in 2026, including full data readout for IPN10200 [4][19] - The company initiated several Phase I oncology studies and expanded its immuno-oncology portfolio with the acquisition of ImCheck Therapeutics [15][14] Regulatory and Clinical Developments - In 2025, Ipsen achieved important regulatory milestones, including the acceptance of tovorafenib for review by the EMA and the approval of Cabometyx for advanced neuroendocrine tumors [9][11] - Positive Phase II data for Iqirvo® and IPN10200 were reported, demonstrating promising efficacy and safety profiles [10][12] Environmental, Social, and Governance (ESG) - Ipsen made progress on its sustainability strategy, achieving a 54% reduction in Scopes 1 & 2 greenhouse gas emissions and sourcing 100% of its global electricity from renewable sources [21][25] - The company received an A rating from CDP for environmental actions and achieved gender parity within its Executive Leadership Team [22]

Core Insights - The U.S. FDA has cleared ArkBio's IND application for AK3280, allowing the initiation of a Phase 2 proof-of-concept clinical trial for idiopathic pulmonary fibrosis (IPF) [1] - The Phase 2 trial is designed to evaluate the efficacy, safety, and pharmacokinetics of AK3280, which is an optimized, small-molecule anti-fibrotic agent [1] - Current IPF therapies have limited clinical benefits and are often associated with gastrointestinal side effects, highlighting the unmet need for better treatment options [1] Company Overview - ArkBio is a commercial-stage biotechnology company focused on innovative therapeutics for respiratory and pediatric diseases, founded in 2014 [1] - The company has developed proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations [1] - Key pipeline assets include Ziresovir (AK0529), AK3280, and AK0901, with strategic partnerships established with multinational pharmaceutical companies and leading academic institutions [1] Clinical Development - The Phase 2 trial for AK3280 is a multi-center, randomized, partially double-blind, placebo- and active-controlled study [1] - Previous Phase 2 results in China showed AK3280's significant clinical activity, including a dose-dependent increase in forced vital capacity (FVC) at Week 24 [1] - AK3280 demonstrated a favorable safety profile with no significant gastrointestinal adverse effects, differentiating it from existing IPF therapies [1] Market Potential - The FDA clearance for the IND is a significant milestone for ArkBio, paving the way for future regulatory submissions and potential commercialization in major markets [1] - There is a substantial unmet need for therapies that offer improved efficacy and safety for patients with IPF, which AK3280 aims to address [1]

Core Viewpoint - AbbVie Inc. has projected 2026 profits above Wall Street estimates, driven by strong sales of its older immunology drug, Humira, despite concerns over future growth due to competition and revenue shortfalls from newer treatments [3][5]. Financial Performance - AbbVie reported fourth-quarter adjusted earnings of $2.71 per share, exceeding the average analyst estimate of $2.65 [4]. - Skyrizi generated $5.01 billion in sales, surpassing the expected $4.82 billion, while Rinvoq posted $2.37 billion, slightly below the consensus estimate of $2.41 billion [4]. - Humira sales declined 25.9% year over year to $1.25 billion but still exceeded expectations of $983.8 million [4]. Future Projections - AbbVie expects combined sales from Rinvoq and Skyrizi to reach approximately $31.6 billion in 2026, achieving its target of over $31 billion in annual sales a year earlier than planned [5]. - Analyst Gavin Clark-Gartner from Evercore ISI noted that guidance and consensus expectations for 2026 and 2027 appear beatable, with buy-side expectations running above consensus for some time [2][6]. Market Dynamics - The stock's pressure is linked to concerns about growth beyond 2028, especially with additional competitors entering the market [2]. - AbbVie is relying on Skyrizi and Rinvoq to offset the decline in Humira sales, which are under pressure from lower-cost biosimilars [3].

Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA) [3] Group 1: Stock Option Awards - On February 9, 2026, the Compensation Committee of Mineralys granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares to two new non-executive employees [1] - The options will vest over a four-year period, with 25% vesting on the first anniversary of the vesting commencement date and 1/48th vesting monthly thereafter, subject to continued service [2] - The restricted stock units will also vest over a four-year period, with 25% vesting on each of the four anniversaries of the vesting commencement date [2] Group 2: Employment Inducement Plan - The awards were granted under Mineralys' 2025 Employment Inducement Incentive Award Plan, which allows for equity awards to new employees [2] - The inducement awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) [2]

Core Insights - Ascendis Pharma is experiencing strong commercial growth for its products, particularly YORVIPATH and SKYTROFA, with significant revenue increases reported for Q4 2025 and full-year 2025 [3][4][7]. Commercial Performance - YORVIPATH generated €187 million in Q4 2025, contributing to a total of €477 million for the full year [3][7]. - SKYTROFA reported Q4 revenue of €53 million and full-year revenue of €206 million, with a U.S. market share of approximately 7% [11]. - The company has prescribed YORVIPATH to over 5,300 patients in the U.S. through nearly 2,400 healthcare providers, indicating a substantial long-term opportunity as less than 5% of U.S. patients are currently on treatment [2][7]. Financial Outlook - Ascendis ended 2025 with €616 million in cash and expects to achieve around €500 million in operating cash flow in 2026, with a long-term goal of at least €5 billion in annual product revenue by 2030 [5][20]. - Total revenue for Q4 2025 was €248 million, with operating expenses of €214 million, resulting in an operating profit of €10 million [17]. Pipeline and Regulatory Updates - The U.S. NDA for TransCon CNP is under review with a PDUFA date set for February 28, 2026, and the company anticipates full enrollment in its trial for infants with achondroplasia by late 2026 [6][13]. - Management highlighted the potential of a once-weekly TransCon PTH candidate, which aims to match the efficacy of daily therapies while improving patient convenience [8][12]. Market Expansion and Strategy - Ascendis plans to launch YORVIPATH in 10 additional countries in 2026, building on its existing commercial presence in over 30 countries [1]. - The company is also working to expand the label for SKYTROFA and is conducting trials to evaluate its growth hormone in additional indications, which could represent a significant market opportunity [10][11].

For Hetlioz, full-year net product sales fell 7% to $71.4 million. Moran said the decline reflected lower volume and price net of deductions amid continued U.S. generic competition, while noting the brand “continued to retain the majority of market share despite generic competition now for over three years.” Ponvory net product sales were $27.4 million, down 2% versus 2024, with the company also noting that certain variable consideration tied to Ponvory sales remains subject to dispute.Total 2025 revenues a ...

Core Viewpoint - Novocure has received FDA approval for Optune Pax® to treat adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, marking a significant advancement in cancer treatment options [1] Group 1: FDA Approval - The FDA approved Optune Pax® for use in adult patients with locally advanced pancreatic cancer [1] - This approval is based on the results from the Phase 3 PANOVA-3 trial [1] Group 2: Clinical Trial Results - The PANOVA-3 trial demonstrated a statistically significant improvement in overall survival for patients treated with Optune Pax® [1] - Importantly, the treatment did not add to the systemic side effects typically associated with existing therapies [1]

Table of Contents As filed with the Securities and Exchange Commission on February 11, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-5024477 (State or Other Jurisdiction of Incorporation or Organization) Primary Standard Industrial Classification Code Number 2929 N Commerce Parkway Miramar, FL 33025 (9 ...

HILLSIDE, NJ / ACCESS Newswire / February 11, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2025. Revenue for the quarter ended December 31, 2025 was $11.3 million compared to $12.6 million for the quarter ended December 31, 2024, a decrease of $1.3 million or 10.3%. ...